FDA approves contrast agent for CNS MRI scans

The U.S. Food and Drug Administration has approved Gadavist (gadobutrol), a contrast agent for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm247207.htm

LEAVE A REPLY

Please enter your comment!
Please enter your name here